PMID- 38008655
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240214
IS  - 1878-3449 (Electronic)
IS  - 0749-2081 (Linking)
VI  - 40
IP  - 1
DP  - 2024 Feb
TI  - The Role of Nurses in the Management of Adverse Events in Patients Receiving 
      First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell 
      Carcinoma.
PG  - 151545
LID - S0749-2081(23)00220-6 [pii]
LID - 10.1016/j.soncn.2023.151545 [doi]
AB  - OBJECTIVES: The recent approval of first-line tyrosine kinase inhibitor plus 
      immuno-oncology agent combination therapy for the treatment of advanced renal 
      cell carcinoma offers substantially improved response rates and survival compared 
      with the previous standard of care. This expansion of treatment options has also 
      led to a greater range and complexity of potential treatment-related adverse 
      events related to overlapping toxicities. The aim of this article is to discuss 
      the management of common treatment-emergent adverse events (AEs) associated with 
      axitinib plus immuno-oncology therapy, highlight the specific roles of oncology 
      nurses in managing these events, and provide AE management resources to aid 
      oncology nurses in their care of patients with advanced renal cell carcinoma. 
      DATA SOURCES: Author experience, journal articles, and treatment guidelines were 
      used. CONCLUSION: The use of oncology nurses and nurse-led innovations to monitor 
      and assess treatments can have a positive impact on the management of AEs in 
      cancer patients by identifying those who are most at risk, providing regular 
      assessment, appropriate patient education, and supporting the monitoring of 
      patient safety. IMPLICATIONS FOR NURSING PRACTICE: Skilled oncology nurses should 
      be a key part of a team that addresses the supportive care needs and management 
      of AEs that are associated with novel cancer treatments. Early and ongoing 
      communication between the patient and oncology nurses regarding the development 
      of adverse events is a critical component of maximizing treatment outcomes and 
      quality of life.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Parreira, Sara
AU  - Parreira S
AD  - CUF Oncology, Lisbon, Portugal.
FAU - Burns, Kathleen
AU  - Burns K
AD  - Dana-Farber Cancer Institute, Massachusetts.
FAU - Moldawer, Nancy
AU  - Moldawer N
AD  - Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 
      California.
FAU - Zomordian, Nazy
AU  - Zomordian N
AD  - UCLA, Department of Urology, California.
FAU - Bandali, Nesan
AU  - Bandali N
AD  - Sunnybrook Odette Cancer Centre, ON, Canada.
FAU - Virdee, Kiran
AU  - Virdee K
AD  - Memorial Sloan Kettering Cancer Center, New York.
FAU - Walsh, Meghara
AU  - Walsh M
AD  - Dana-Farber Cancers Institute, Massachusetts.
FAU - Kelly, Daniel
AU  - Kelly D
AD  - Cardiff University, Wales, UK.
FAU - Rao, Dharanija
AU  - Rao D
AD  - Pfizer Inc., NY, USA.
FAU - Teresi, Rosemary
AU  - Teresi R
AD  - Pfizer Inc, NY, USA.
FAU - Wood, Laura S
AU  - Wood LS
AD  - Cleveland Clinic Cancer Center, Cleveland, Ohio (retired). Electronic address: 
      woodls401@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231125
PL  - United States
TA  - Semin Oncol Nurs
JT  - Seminars in oncology nursing
JID - 8504688
RN  - C9LVQ0YUXG (Axitinib)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy/chemically induced
MH  - Axitinib/adverse effects
MH  - *Kidney Neoplasms/drug therapy/chemically induced
MH  - Quality of Life
MH  - Protein Kinase Inhibitors
OTO - NOTNLM
OT  - Adverse event management
OT  - Avelumab
OT  - Axitinib
OT  - Nursing care
OT  - Pembrolizumab
OT  - Renal cell carcinoma
COIS- Declaration of competing interest Sara Parreira, Kathleen Burns, Nancy Moldawer, 
      Nazy Zomordian, Nesan Bandali, Kiran Virdee, Meghara Walsh and Laura Wood have no 
      disclosures to report. Daniel Kelly is a member of a team of Grant Recipients 
      from Pfizer to conduct an independent medical education program entitled 
      "RCC4Nurses: Improving quality of nursing care in metastatic renal cell 
      carcinoma" with the University of Glasgow and the European Oncology Nursing 
      Society. Dharanija Rao and Rosemary Teresi are full-time employees and hold stock 
      or stock options in Pfizer.
EDAT- 2023/11/27 00:43
MHDA- 2024/02/11 07:43
CRDT- 2023/11/26 21:59
PHST- 2023/04/18 00:00 [received]
PHST- 2023/10/17 00:00 [revised]
PHST- 2023/10/20 00:00 [accepted]
PHST- 2024/02/11 07:43 [medline]
PHST- 2023/11/27 00:43 [pubmed]
PHST- 2023/11/26 21:59 [entrez]
AID - S0749-2081(23)00220-6 [pii]
AID - 10.1016/j.soncn.2023.151545 [doi]
PST - ppublish
SO  - Semin Oncol Nurs. 2024 Feb;40(1):151545. doi: 10.1016/j.soncn.2023.151545. Epub 
      2023 Nov 25.